Literature DB >> 29049130

Explanatory Versus Pragmatic Trials: An Essential Concept in Study Design and Interpretation.

Zamir Merali1, Jefferson R Wilson.   

Abstract

Randomized clinical trials often represent the highest level of clinical evidence available to evaluate the efficacy of an intervention in clinical medicine. Although the process of randomization serves to maximize internal validity, the external validity, or generalizability, of such studies depends on several factors determined at the design phase of the trial including eligibility criteria, study setting, and outcomes of interest. In general, explanatory trials are optimized to demonstrate the efficacy of an intervention in a highly selected patient group; however, findings from these studies may not be generalizable to the larger clinical problem. In contrast, pragmatic trials attempt to understand the real-world benefit of an intervention by incorporating design elements that allow for greater generalizability and clinical applicability of study results. In this article we describe the explanatory-pragmatic continuum for clinical trials in greater detail. Further, a well-accepted tool for grading trials on this continuum is described, and applied, to 2 recently published trials pertaining to the surgical management of lumbar degenerative spondylolisthesis.

Entities:  

Mesh:

Year:  2017        PMID: 29049130     DOI: 10.1097/BSD.0000000000000588

Source DB:  PubMed          Journal:  Clin Spine Surg        ISSN: 2380-0186            Impact factor:   1.876


  5 in total

Review 1.  The need for increased pragmatism in cardiovascular clinical trials.

Authors:  Muhammad Shariq Usman; Harriette G C Van Spall; Stephen J Greene; Ambarish Pandey; Darren K McGuire; Ziad A Ali; Robert J Mentz; Gregg C Fonarow; John A Spertus; Stefan D Anker; Javed Butler; Stefan K James; Muhammad Shahzeb Khan
Journal:  Nat Rev Cardiol       Date:  2022-05-17       Impact factor: 49.421

2.  Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England.

Authors:  Matthew James Smith; Aurélien Belot; Matteo Quartagno; Miguel Angel Luque Fernandez; Audrey Bonaventure; Susan Gachau; Sara Benitez Majano; Bernard Rachet; Edmund Njeru Njagi
Journal:  Cancers (Basel)       Date:  2021-11-19       Impact factor: 6.639

3.  A patient decision aid for breast cancer patients deciding on their radiation treatment, no change in decisional conflict but better informed choices.

Authors:  D B Raphael; N S Russell; B Winkens; J M Immink; P G Westhoff; M C Stenfert Kroese; M R Stam; N Bijker; C M J van Gestel; T van der Weijden; L J Boersma
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-08-29

4.  Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.

Authors:  D B Raphael Daniela; N S Russell; E van Werkhoven; J M Immink; D P G Westhoff; M C Stenfert Kroese; M R Stam; L M van Maurik; C M J van Gestel; T van der Weijden; L J Boersma
Journal:  Breast Cancer Res Treat       Date:  2020-10-24       Impact factor: 4.872

Review 5.  What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis.

Authors:  Rachael M Burke; Hannah M Rickman; Vindi Singh; Elizabeth L Corbett; Helen Ayles; Andreas Jahn; Mina C Hosseinipour; Robert J Wilkinson; Peter MacPherson
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 6.707

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.